MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 21, 2006--Geron Corporation (Nasdaq:GERN) announced today the presentation of new data supporting the development of TAT0002, a small molecule telomerase activator for the treatment of HIV/AIDS, at the XVI International AIDS Conference in Toronto.
